collaborations

The Bill & Melinda Gates Foundation

Affinivax was founded with an initial seed investment from The Bill & Melinda Gates Foundation in 2014. This investment fits with the focus of the Foundation to identify and support the latest vaccine approaches that can impact global health by improving coverage, efficacy, safety and access to life-saving treatments. Affinivax shares this common vision with the Foundation and will continue to seek opportunities where MAPS vaccines could be developed to impact infectious diseases impacting children and adults in the developing world.

Trade marks are owned by or licensed to the GSK group of companies.
©2022 GSK group of companies or its licensor.

Back to Top
 

This links to an external website.

Continue